Mentice AB stock analysis
Want to see SE:MNTC full AI Analyst Report?
Mentice AB (MNTC) Stock Price & Analysis
MNTC Stock Chart & Stats
- Day’s Range
- SEK 13.20 - SEK 14.35
- 52-Week Range
- SEK 12.00 - SEK 18.95
- Previous Close
- SEK 15.05
- Volume
- N/A
- Average Volume (3M)
- 15.95K
- Market Cap
- SEK 378.29M
- Enterprise Value
- SEK 376.88M
- Total Cash (Recent Filing)
- SEK 61.07M
- Total Debt (Recent Filing)
- SEK 13.56M
- Price to Earnings (P/E)
- ―
- Beta
- 0.86
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- 0.44
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
The reported revenue growth indicates that Mentice is expanding its commercial base and sustaining demand for its simulation and training solutions. Continued top-line expansion can support operating leverage, broaden customer adoption, and provide a foundation for improving earnings over the next several quarters.
Conservative Balance Sheet
Very low leverage and a sizable equity base give Mentice meaningful financial flexibility. This reduces pressure from interest obligations, improves resilience if operating conditions weaken, and leaves more capacity to fund product development, customer programs, or other growth initiatives without relying heavily on debt.
Improving Cash Generation
The return to positive trailing-twelve-month operating and free cash flow is an important improvement in the company’s financial trajectory. If maintained, internally generated cash can support ongoing operations and investment while reducing dependence on external financing during the transition toward profitability.
Bears Say
Persistent Losses
Mentice has improved its profitability trend but has not yet established positive EBIT or net income. Continued losses can constrain reinvestment, weaken the quality of reported growth, and make the business more dependent on sustained execution before its operating model produces durable earnings.
Volatile Cash Flow
Although trailing cash generation is currently positive, large year-to-year swings indicate that conversion from business activity into cash has not been consistent. This variability can complicate planning, reduce confidence in self-funded growth, and create periods where operations require greater financial support.
Negative Return On Equity
Negative ROE shows that the substantial equity base is not currently generating a positive return because losses remain unresolved. Until profitability improves, capital efficiency will stay weak, limiting the economic benefit of the balance-sheet strength and potentially slowing long-term compounding.
Mentice AB News
MNTC FAQ
What was Mentice AB’s price range in the past 12 months?
What is Mentice AB’s market cap?
When is Mentice AB’s upcoming earnings report date?
How were Mentice AB’s earnings last quarter?
Is Mentice AB overvalued?
Does Mentice AB pay dividends?
What is Mentice AB’s EPS estimate?
How many shares outstanding does Mentice AB have?
What happened to Mentice AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Mentice AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Mentice AB
Mentice AB (publ), founded in 1998 and headquartered in Gothenburg, Sweden, specializes in delivering advanced endovascular simulation solutions. These are utilized by educational institutions, healthcare systems, and medical device manufacturers globally, with the company's operations spanning across Europe, the Middle East, Africa, the Asia Pacific region, and the Americas. Its business is structured across distinct segments focusing on the Medical Device Industry, Healthcare Systems, and Strategic Alliances. The company offers a comprehensive suite of software modules designed for training in a wide array of interventional procedures. These include acute ischemic stroke, atrial septal defect/patent foramen ovale occlusion, aortic valve implantation, endovascular aortic repair, below-the-knee, carotid, and renal interventions, along with patient-specific simulations. The portfolio further encompasses advanced and essential coronary procedures, intermediate coronary, left atrial appendage occlusion, neurovascular coiling and thrombectomy, peripheral angiography, prostatic and uterine artery embolization, radiation safety, transarterial chemoembolization, transseptal puncture, vascular trauma, and cardiac rhythm management. Additionally, Mentice provides crucial support for interventionalists transitioning from transfemoral to transradial access techniques. Beyond software, Mentice's product line features sophisticated medical simulators for endovascular therapies, accompanied by compatible accessories and extensions. They also supply specialized silicone vasculature, as well as cardiac, vascular, and neurovascular flow systems. Innovative digital offerings include the Mentice Right Heart Cath App, a mobile tool for interactive exploration of right heart catheterization procedures, and the Mentice Live Learning Center, which facilitates remote learning through its VIST G endovascular simulation platform. All these comprehensive solutions are engineered to educate, train, and significantly enhance the skills of medical professionals.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Frans Matthieu Venker
- Employees
- 109
- Website
- www.mentice.com
- Address
- Odinsgatan 10, Gothenburg, VG, 411 03, SE
Mentice AB (MNTC) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 4 | 8 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 6 | 0 | 6 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| SE:GETI.BGetinge | ||
| SE:XVIVOXvivo Perfusion AB | ||
| SE:BACTI.BBactiguard Holding AB | ||
| SE:SECT.BSectra AB Class B | ||
| SE:HEARTScandinavian Real Heart AB |







